A 22-month survival benefit was seen for a subset of ALS patients whose disease did not progress when treated with NP001 in ...

MNDs are neurological disorders that destroy motor neurons, the cells that control skeletal muscle activity such as walking, breathing, speaking, and swallowing.

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that it has received approval from USFDA to ...

Motor neuron disease usually refers to amyotrophic lateral sclerosis, but it can also refer to other kind of neurodegenerative disease that affect the motor neurons, such as progressive primary ...

DNL343 For The Treatment Of Patients With Amyotrophic Lateral Sclerosis As I stated directly above, Denali Therapeutics reported that it had failed to meet the primary endpoint of the phase 2/3 ...

Compared to placebo, the study did not meet the primary endpoint of efficacy in slowing disease progression. The primary endpoint was evaluated as a change in disease severity over time as ...

US-based biotechnology company Denali Therapeutics has reported that a Phase II/III trial of DNL343 for amyotrophic lateral sclerosis (ALS) failed to meet its primary endpoint. The primary analysis ...

Introduction: T regulatory cells (Tregs) inversely correlate with disease progression in Amyotrophic Lateral Sclerosis (ALS ... in the design of clinical trials for ALS therapy. The primary objective ...

today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment of amyotrophic lateral sclerosis (ALS). The ...